GREAT-WALL-MOTOR
5.6.2019 11:19:08 CEST | Business Wire | Press release
At 12:06 on June 5, 2019, CZ-11 Solid-fuel Space Launch Vehicle (CZ-11 WEY) sees its first sea launch on the Yellow Sea, successfully sending seven satellites into the preset orbit and ushering in a new era of CASC development. The leading Chinese luxury SUV brand WEY is the first business partner of CASC. Both parties jointly call this launch vehicle as “CZ-11 WEY”, which marks a new breakthrough in business model of CASC. In addition, the Joint Technology Innovation Center co-initiated by CASC and WEY aims to put technologies into practice in the fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy through steady progress, so that the aero technology can be readily available.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005423/en/
CZ-11 Space Launch Vehicle is the first and only type of solid-fuel launch vehicles in the CZ Launch Vehicle Family. It is nearly 21 meters long and 58 tons weigh. Boasting a take-off thrust of 120 tons, it can carry up to 500 kg of payloads into the sun-synchronous orbit at a height of 500 km. This sea launch of CZ-11 WEY crystallizes the breakthroughs in a number of key technologies, such as wireless remote control at the front and rear terminals, independent intelligent security control on launcher, aiming of mobile base launching on the sea. CZ-11 Space Launch Vehicle has not only achieved China’s first-ever sea launch and low-inclination launch, but also created a new launch mode for Chinese launch vehicles into the space.
In conjunction with this sea launch, CASC and WEY steadily advance technical exchanges and cooperation in two fields. Both parties will promote integration in four fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy. They are committed to strongly empowering the independent R&D and manufacturing and creating greater market opportunities and economic value for CASC. Moreover, through technology application in the automotive industry, the aerospace technology can be readily available.
It is worth mentioning that Creative Experience Activity of “Dialogue with Parallel Universe” is jointly held by WEY and CASC. Through digital transmitter mounted on CZ-11 WEY Satellite, the voices of many consumers are transmitted to the outer space in the form of electric wave to “dialogue across the space” with another themselves in parallel universe. Compared with the international program of “Send Your Name to Mars with NASA’s next Mars Rover”, this sea launch is such a magnificent feat that retains the peoples’ voices and names in the space earlier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005423/en/
Contact:
Great Wall Motor Liu Jian +8618241766066 liujian@dsconsulting.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
